Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

Redesigning antidepressant drug discovery. [Guest Editorial]


Holsboer,  Florian
Max Planck Institute of Psychiatry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Holsboer, F. (2014). Redesigning antidepressant drug discovery. [Guest Editorial]. Dialogues in clinical neuroscience, 16(1), 5-7.

Cite as: http://hdl.handle.net/11858/00-001M-0000-0027-7780-6
Antidepressant drug discovery and development have been put on hold by many pharmaceutical companies. The main reason for this is the negative efficacy studies with novel specific drugs. Here I argue that the main obstacles are the absence of gene tests and biomarkers as an integral part of a diagnostic process. Further, too much emphasis has been put on validating drug candidates in animal models of psychiatric disorders. A more rapid transfer of drug candidates into human research is necessary to overcome current obstacles that prevent the discovery of next-generation antidepressants.